XML 42 R18.htm IDEA: XBRL DOCUMENT
v3.20.2

Goodwill and Other Intangible Assets | 6 Months Ended
--- | ---
Oct. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Other Intangible Assets | Goodwill and Other Intangible Assets Goodwill The following table presents the changes in the carrying amount of goodwill by segment:
(in millions) | Cardiac and Vascular Group |  | Minimally Invasive Therapies Group |  | Restorative Therapies Group |  | Diabetes Group |  | Total
April 24, 2020 | $ | 6,831 |  |  | $ | 20,176 |  |  | $ | 10,920 |  |  | $ | 1,914 |  |  | $ | 39,841 |
Goodwill as a result of acquisitions | — |  |  | — |  |  | 35 |  |  | 346 |  |  | 381 |
Purchase accounting adjustments | — |  |  | — |  |  | 3 |  |  | — |  |  | 3 |
Currency translation and other | 95 |  |  | 772 |  |  | 119 |  |  | 1 |  |  | 987 |
October 30, 2020 | $ | 6,926 |  |  | $ | 20,948 |  |  | $ | 11,077 |  |  | $ | 2,261 |  |  | $ | 41,212 |
The Company assesses goodwill for impairment annually as of the first day of the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Impairment testing for goodwill is performed at the reporting unit level. The test for impairment of goodwill requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis. The Company did not recognize any goodwill impairment during the three and six months ended October 30, 2020 or October 25, 2019. Intangible Assets The following table presents the gross carrying amount and accumulated amortization of intangible assets:
| October 30, 2020 |  | April 24, 2020
(in millions) | Gross Carrying Amount |  | Accumulated Amortization |  | Gross Carrying Amount |  | Accumulated Amortization
Definite-lived: |  |  |  |  |  |  |
Customer-related | $ | 17,017 |  |  | $ | (5,567) |  |  | $ | 16,963 |  |  | $ | (5,065) |
Purchased technology and patents | 11,041 |  |  | (4,767) |  |  | 10,742 |  |  | (4,354) |
Trademarks and tradenames | 469 |  |  | (241) |  |  | 464 |  |  | (232) |
Other | 78 |  |  | (58) |  |  | 75 |  |  | (53) |
Total | $ | 28,605 |  |  | $ | (10,633) |  |  | $ | 28,244 |  |  | $ | (9,704) |
Indefinite-lived: |  |  |  |  |  |  |
IPR&D | $ | 440 |  |  | $ | — |  |  | $ | 523 |  |  | $ | — |
The Company assesses definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of an intangible asset (asset group) may not be recoverable. When events or changes in circumstances indicate that the carrying value of an intangible asset may not be recoverable, the Company calculates the excess of an intangible asset's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. The Company did not recognize any definite-lived intangible asset charges during the three and six months ended October 30, 2020. The Company recognized $33 million of definite-lived intangible asset charges during the three and six months ended October 25, 2019 in connection with exit of businesses within the Restorative Therapies Group segment. Intangible asset impairment charges are recognized in other operating expense, net in the consolidated statements of income. The Company assesses indefinite-lived intangibles for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate that the carrying value may be impaired. The Company did not recognize any indefinite-lived intangible asset impairments during the three and six months ended October 30, 2020 or October 25, 2019. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future. Amortization Expense Intangible asset amortization expense for the three months ended October 30, 2020 and October 25, 2019 was $443 million and $441 million, respectively. For the six months ended October 30, 2020 and October 25, 2019, intangible asset amortization expense was $884 million and $881 million, respectively. Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at October 30, 2020, excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows:
(in millions) | Amortization Expense
Remaining 2021 | $ | 888 |
2022 | 1,738 |
2023 | 1,674 |
2024 | 1,643 |
2025 | 1,617 |
2026 | 1,604 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration